Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 23, 2018 - The FDA announced the approval of Shire’s Takhzyro (lanadelumab-flyo), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.
Return to publications